The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

24 Jan 2024 17:30

Arix Bioscience PLC (ARIX) Holding(s) in Company 24-Jan-2024 / 17:30 GMT/BST


TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Arix Bioscience Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an “X”)

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify) iii:

 

3. Details of person subject to the notification obligation iv

Name

RTW Investments, LP

City and country of registered office (if applicable)

New York, USA

4. Full name of shareholder(s) (if different from 3.) v

Name

RTW Biotech Opportunities Operating Ltd

City and country of registered office (if applicable)

St Peter Port, Guernsey

5. Date on which the threshold was crossed or reached vi:

17/01/2024

6. Date on which issuer notified (DD/MM/YYYY):

22/01/2024

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

25.52

0.00%

25.52%

33,023,210

Position of previous notification (if

applicable)

n/a

n/a

n/a

 

             

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BD045071

0

33,023,210

0.00%

25.52%

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

33,023,210

25.52%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/ Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/ Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

                   

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an “X”)

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

 

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Roderick Wong

 

 

 

RTW Investments GP LLC

 

 

 

RTW Investments, LP

 

 

 

RTW Biotech Opportunities Ltd

 

 

 

RTW Biotech Opportunities Operating Ltd

25.52%

0.00%

25.52%

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional information xvi

 

         

 

Place of completion

London, UK

Date of completion

19/01/2024

 

 

 

 

 

 


Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
ISIN:GB00BD045071
Category Code:HOL
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories: 2.3. Major shareholding notifications
Sequence No.:299502
EQS News ID:1822379
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
11th Dec 20197:05 amPRNIterum announces topline Phase 3 data
9th Dec 20197:01 amPRNAutolus announces new AUTO3 data at ASH
9th Dec 20197:00 amPRNAutolus announces key new data at ASH
22nd Nov 20199:57 amPRNHolding(s) in Company
21st Nov 201912:06 pmPRNHarpoon and AbbVie announce licensing and option deal
7th Nov 201912:22 pmPRNAutolus reports Q3 2019 financial results
7th Nov 20197:22 amPRNChange of Broker
6th Nov 20192:31 pmPRNAutolus to present new data at the ASH Annual Meeting
6th Nov 20197:02 amPRNArtios expands DDR pipeline with new asset
17th Oct 20191:40 pmPRNHolding(s) in Company
16th Oct 20198:00 amPRNAura reports updated Phase 1b/2 clinical data for AU-011
15th Oct 20193:20 pmPRN]Holding(s) in Company
3rd Oct 20197:06 amPRN2019 Capital Markets Day
2nd Oct 20197:00 amPRNManagement change
30th Sep 20197:00 amPRNArix co-leads EUR 20m Series A financing in STipe
17th Sep 20197:47 amPRNAmplyx unveils expanded pipeline and Phase 2 data
28th Aug 20197:00 amPRNInterim results for the six months ended 30 June 2019
20th Aug 20197:25 amPRNNotice of Results
8th Aug 20191:03 pmPRNAutolus reports Q2 2019 financial results
1st Aug 20197:00 amPRNTotal Voting Rights
8th Jul 20193:34 pmPRNHolding(s) in Company
3rd Jul 20197:00 amPRNIssue of Ordinary Shares, TVR, PDMR Notifications
28th Jun 20193:22 pmPRNHolding(s) in Company
25th Jun 20194:17 pmPRNHolding(s) in Company
18th Jun 20195:23 pmPRNHolding(s) in Company
3rd Jun 20195:51 pmPRNCorrection: Result of AGM
3rd Jun 20195:16 pmPRNResult of AGM
3rd Jun 20197:00 amPRNTotal Voting Rights
10th May 20197:00 amPRNDirector/PDMR Shareholding
1st May 20197:00 amPRNIssue of Ordinary Shares and Total Voting Rights
16th Apr 20197:00 amPRNAutolus announces closing of public offering
11th Apr 20197:00 amPRNAutolus announces pricing of public offering
9th Apr 20197:00 amPRNAutolus announces launch of proposed public offering
2nd Apr 20197:08 amPRNAura completes $40 million Series D financing
1st Apr 20196:10 pmPRNAutolus presents initial AUTO1 data at AACR
28th Mar 20197:00 amPRNAnnual Results for the year ended 31 December 2018
28th Mar 20197:00 amPRNBoard changes
26th Mar 201910:17 amPRNAutolus hosts R&D day and provides update on AUTO3
20th Mar 201912:23 pmPRNNotice of Results
18th Mar 20197:00 amPRNArix co-leads $63m Series B investment round for Imara
19th Feb 201912:12 pmPRNAutolus announces updated results from CARPALL trial
19th Feb 20197:00 amPRNManagement and Board changes
14th Feb 20197:00 amPRNHarpoon closes initial public offering
8th Feb 20197:09 amPRNHarpoon prices Nasdaq IPO
1st Feb 201910:38 amPRNTotal Voting Rights
29th Jan 20192:25 pmPRNUpdate on Harpoon proposed IPO in the United States
3rd Jan 20197:00 amPRNIssue of Ordinary Shares and Total Voting Rights
28th Dec 20187:00 amPRNHarpoon announces proposed public offering in the US
11th Dec 20187:00 amPRNArix appoints Dr Christian Schetter as EIR
3rd Dec 20187:00 amPRNAutolus presents initial AUTO3 clinical data at ASH

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.